Myriad licenses cancer technology to Salmedix
Myriad’s technology using the single R-enantiomer of etodolac, biochemically triggers cellular suicide in lymphocytes. This technology will be used by Salmedix to further its clinical drug candidate SDX-101
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.